---
layout: default
title: Insulin Glargine
parent: 僅模型預測 (L5)
nav_order: 185
evidence_level: L5
indication_count: 10
---

# Insulin Glargine
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Insulin Glargine: From Diabetes Mellitus to Autoimmune Oophoritis

## One-Sentence Summary

> Insulin glargine is a long-acting basal insulin analogue originally used for the management of Type 1 and Type 2 diabetes mellitus.
> The TxGNN model predicts it may be relevant to **Autoimmune Oophoritis**,
> but this association is currently supported by **0 clinical trials** and **0 publications**, and appears to reflect a comorbidity pattern rather than a direct treatment signal.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Diabetes mellitus (Type 1 and Type 2) |
| Predicted New Indication | Autoimmune Oophoritis |
| TxGNN Prediction Score | 99.88% |
| Evidence Level | L5 |
| Norway Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available. Based on known information, insulin glargine is a long-acting recombinant human insulin analogue used to provide basal glycemic control in diabetes; its efficacy in Type 1 and Type 2 diabetes is well established, but there is no known pharmacological pathway linking it to ovarian autoimmune tissue destruction.

The repurposing rationale explicitly notes that this signal likely arises from **co-occurrence rather than causation**: autoimmune oophoritis frequently co-occurs with Type 1 diabetes mellitus as part of Autoimmune Polyglandular Syndrome type 2 (APS-2), where the knowledge graph may have learned the disease-disease relationship rather than a drug-disease treatment relationship.

Because insulin regulates blood glucose and has no known immunomodulatory effect on ovarian autoimmunity, the mechanistic plausibility of this prediction as a *treatment* signal is low. This should be interpreted as a comorbidity artifact of the model rather than a genuine repurposing opportunity.

---

## Clinical Trial Evidence

Currently no related clinical trials registered

---

## Literature Evidence

Currently no related literature available

---

## Norway Market Information

No marketing authorizations are currently on file — Norway market status is recorded as **Not Marketed**, with 0 total licenses.

---

## Safety Considerations

Please refer to the package insert for safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
This prediction is at the lowest evidence tier (L5) — model score only, with zero supporting clinical trials or literature. The underlying rationale itself flags the association as a likely comorbidity artifact (via APS-2 co-occurrence with T1DM) rather than a plausible causal treatment mechanism, so it does not meet the bar to advance past S0.

**To proceed, the following is needed:**
- Independent literature or mechanistic evidence directly linking insulin (or insulin signaling pathways) to autoimmune oophoritis treatment, not merely diabetes comorbidity
- TFDA/regulatory label data (warnings, contraindications) — currently a **Blocking** data gap (DG001), required before any S1 safety screening
- DrugBank-sourced mechanism of action (DG002, High severity) to properly assess mechanistic plausibility
- Expert endocrinology/reproductive immunology review before any further evaluation

**Note on other candidates in this evidence pack:** Among the 10 predictions provided for insulin glargine, rank #6 (**pancreatic agenesis**) has a stronger mechanistic basis — pancreatic agenesis (e.g., PDX1/PTF1A defects) causes absolute insulin deficiency, for which insulin replacement is standard of care by direct causal logic (L4, decision stage S1, "Research Question"). This may warrant separate evaluation, though its supporting literature is currently indirect (general T2DM insulin therapy reviews and animal case reports) rather than pancreatic-agenesis-specific. Several other ranked items (drug-induced/centrifugal/pressure-induced/idiopathic lipodystrophy) show a **reversed-causality warning** — insulin injection is a known *cause* of localized lipoatrophy/lipohypertrophy, not a treatment for it, and should be flagged as a safety signal rather than screened as a repurposing candidate.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

